Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Gross Margin (2017 - 2026)

Organogenesis Holdings has reported Gross Margin over the past 9 years, most recently at 43.72% for Q4 2025.

  • For Q4 2025, Gross Margin fell 3176.0% year-over-year to 43.72%; the TTM value through Dec 2025 reached 61.97%, down 1402.0%, while the annual FY2025 figure was 61.97%, 1402.0% down from the prior year.
  • Gross Margin for Q4 2025 was 43.72% at Organogenesis Holdings, down from 75.97% in the prior quarter.
  • Over five years, Gross Margin peaked at 78.05% in Q2 2022 and troughed at 43.72% in Q4 2025.
  • A 5-year average of 73.93% and a median of 75.59% in 2021 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: soared 558bps in 2021 and later tumbled -3176bps in 2025.
  • Year by year, Gross Margin stood at 74.51% in 2021, then rose by 3bps to 76.53% in 2022, then dropped by -6bps to 72.13% in 2023, then increased by 5bps to 75.48% in 2024, then tumbled by -42bps to 43.72% in 2025.
  • Business Quant data shows Gross Margin for ORGO at 43.72% in Q4 2025, 75.97% in Q3 2025, and 72.64% in Q2 2025.